I agree. After this initial shock, MYGN will stair climb back to it's 52 wk highs again in no time. Earnings report last May 7 were above expectations (revenue up 21%, earnings up 34%), and the company raised 2013 revenue guidance again, from $575-585M to $595-600M, and EPS guidance from $1.55-1.58 to $1.65-1.67. IMO, sellers the past 2 trading days will start re-investing again very soon. In fact, Myriad Genetics was upgraded to Outperform from Market Perform at JMP Securities, citing valuation and said the Supreme Court decision removes an overhang.